Fig. 2From: Sunitinib added to FOLFIRI versus FOLFIRI in patients with chemorefractory advanced adenocarcinoma of the stomach or lower esophagus: a randomized, placebo-controlled phase II AIO trial with serum biomarker programKaplan-Meier curves for progression-free survival and overall survival in the primary analysis population (ITT). Hazard ratios estimated by Cox proportional hazards model. PFS, progression-free survival; HR, hazard ratio; ITT, intention-to-treatBack to article page